|Mr. Daniel S. Lynch||Exec. Chairman||52.54k||N/A||1958|
|Mr. J. Jeffrey Goater||CEO, Pres & Director||658.62k||N/A||1975|
|Dr. Vito J. Palombella||Chief Scientific Officer||505.02k||N/A||1963|
|Dr. Robert W. Ross||Chief Medical Officer||495.01k||N/A||1974|
|Ms. Jessica Fees||Sr. VP of Fin. & Bus. Operations and Treasurer||N/A||N/A||1972|
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Surface Oncology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.